In conclusion, the SGLT2 inhibitor ipragliflozin showed anti-albuminuric effects regardless of the presence/absence of renal dysfunction; however, this effect may differ according to the presence or absence of renal dysfunction. The gene discussed is SLC5A2; the disease is Abnormal renal physiology.